Sign in
Taking peoplePhase 3

Bevacizumab or dexamethasone as first treatment for brain damage after radiation

Compares bevacizumab with dexamethasone for symptomatic radiation necrosis in people with glioma or brain metastases.

Key facts

Who runs it
The Netherlands Cancer Institute
Where
Netherlands6 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Status
Recruiting
Phase
Phase 3
People taking part
408 people, planned
Started
19 Jun 2025
Expected to end
Jul 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bevacizumab
  • Dexamethasone
Record updated
13 July 2026

Who can take part

The trial is looking for adults with symptoms from brain tissue damage caused by radiation (radiation necrosis) after radiation for high-grade glioma or brain metastases. It compares bevacizumab with dexamethasone as the first treatment.

Age
18 years and older
Sex
All sexes
Disease stage
First episode of symptomatic radiation necrosis, at least 3 months after focal (re-)irradiation, with no sign of tumour growth. KPS score ≤ 90, plus a loss of at least two points in one NANO domain, or a headache of at least 5/10 for at least 10 days despite paracetamol and/or an NSAID. Brain metastases from any solid tumour, or high-grade glioma confirmed by tissue test (WHO 2021, grade 3-4).
Earlier treatment
No more than 1 mg/day dexamethasone in the 8 weeks before randomization, except higher doses for the necrosis in the last 3 weeks. Bevacizumab less than 6 months before the necrosis diagnosis is not allowed.
Biomarker or test result
For glioma: tumour types defined by IDH status or 1p/19q codeletion as listed in WHO 2021 criteria.
Main reasons for not taking part
  • Life expectancy under 3 months
  • Signs of brain herniation needing urgent surgery
  • Serious heart or blood vessel disease, bleeding problems, or platelet count < 75x109/L
  • Creatinine clearance <30 mL/min or a lot of protein in the urine
  • Pregnancy or breastfeeding
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Inclusion all patients (both HGG and BM):
  • Age ≥ 18 years old
  • First episode of sCRN ≥ 3 months after completion of focal (re-)irradiation, as determined by the local Multidisciplinary Neuro-Oncology Board. A clear working diagnosis of CRN without evidence of a combination with tumour progression is required
  • KPS score ≤ 90 and either (a) a minimum loss of two points in at least one domain of the Neurologic Assessment in Neuro-Oncology (NANO) scale as compared to the maximum score of that domain due to sCRN, or (b) a headache attributable to sCRN with an average intensity ≥5/10 on the NRS, persisting for ≥10 consecutive days, with inadequate relief despite an adequate trial of paracetamol and/or an NSAID unless these medications are contra-indicated or not tolerated
  • Maximum daily dexamethasone use of 1 mg/day for the 8 weeks preceding randomization; Dexamethasone may have been prescribed for various indications, except for managing (ongoing) cerebral edema; Higher doses of dexamethasone are permitted 3 weeks immediately preceding randomization if used specifically for the treatment of sCRN
  • Able to understand the patient information, online tests and questionnaires
  • Written informed consent; Inclusion BM:
  • BM of solid tumour, including all primary tumour types; Inclusion HGG:
  • A confirmed histological diagnosis of high-grade diffuse glioma according to WHO 2021 criteria, including: astrocytoma, IDH-mutant, grade 3-4; astrocytoma, IDH-wildtype (sybtype molecular glioblastoma); oligodendroglioma, 1p/19q codeleted, grade 3; diffuse glioma, NEC, grade 3-4; or glioblastoma, IDH-wildtype, grade 4

Who cannot take part

  • Prior treatment with bevacizumab <6 months before diagnosis of sCRN
  • Impending radiological or clinical signs of brain herniation necessitating immediate decompressive surgery
  • Any comorbidity or condition that prevents safe administration of the studied medication, determined by the treating physician, including but not limited to:; Intolerance for murine proteins; Hypersensitivity or allergy to the active substance or to any of the excipients of bevacizumab or dexamethasone; Nephrotic syndrome or abnormal renal function; o Calculated (Cockcroft-Gault) or measured creatinine clearance <30 mL/min; urine dipstick for proteinuria ≥ 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein/24 hr; Clinical significant cardiovascular disease; Uncontrolled hypertension (systolic BP >150mmHg and/or diastolic >100mmHg) despite the use of ≥ 3 antihypertensive drugs; Previous hypertensive crisis, hypertensive encephalopathy or previous reversible posterior leukoencephalopathy syndrome (RPLS); Non tumour related vascular event (e.g. cerebral or cardiac ischemia/bleeding (including transient ischemic attack, cerebral ischemia, unstable angina or angina requiring intervention, myocardial infarction), peripheral arterial thrombus, peripheral artery disease, deep venous thrombosis, lung embolism) < 6 months; History of aortic aneurysm or dissection; Congestive heart failure NYHA II-IV; History of gastro-intestinal fistula, perforation or abscess < 6 months; History of bleeding; Relevant pulmonary hemorrhage/ hemoptysis < 1 month or the presence of a pulmonary lesion with a high risk of bleeding (= central lung tumour and/or untreated squamous cell carcinoma) according to the treating physician; Active gastrointestinal bleeding < 6 months; Evidence of recent intracranial hemorrhage on MRI brain <3 months. Asymptomatic presence of hemosiderin depositions or punctate hemorrhage in the tumour do not serve as a ground for exclusion; Excess risk of bleeding; History or evidence of inherited bleeding diathesis or significant coagulopathy with the risk of bleeding; Decreased platelet count < 75x109/L; Risk of wound healing complications; Significant non-healing wound, (peptic) ulcer or bone fracture; Major surgical procedure (including open biopsy) or significant traumatic injury within 28 days prior to first study treatment or planned surgical procedure within the following next 28 days after planned study inclusion; Minor surgical procedure, stereotactic/core biopsy, fine needle aspiration within 7 days prior to first study treatment; High-dose radiotherapy to the mediastinum, abdomen, or lower pelvis; administration of bevacizumab should only be considered after prior consultation with a pulmonologist or oncologist; Pregnancy or lactation. Women of child bearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to randomization. WOCBP and female partners of male patients must comply with adequate contraception methods as requested by the study protocol; Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the study treatment, affect patient compliance or place the patient at high risk for treatment-related complications according to the treating physician; Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another interventional study In case of uncertainty, consult the principal investigator of the study site
  • A potential subject who meets any of the following criteria will be excluded from participation in this study, both for the BM and HGG group:
  • Life expectancy <3 months

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in Netherlands.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality of life (QoL). The first-line therapy for symptomatic CRN (sCRN) is corticosteroids, primarily dexamethasone, which often leads to complications, refractory symptoms, and interference with anti-cancer treatment. Since 2017, bevacizumab, an antibody against Vascular Endothelial Growth Factor (VEGF), has been used in a second-line treatment setting for refractory sCRN. A small randomized clinical trial (RCT) has shown that bevacizumab significantly diminishes cerebral edema on MRI and decreases clinical symptoms of sCRN in irradiated glioma patients. Several non-randomized clinical studies demonstrated a beneficial radiological and clinical effect of bevacizumab in patients with sCRN after irradiation for BM. The optimal first-line treatment for sCRN is currently unknown. Effective and safe first-line treatment of sCRN will optimize the patient's well-being and health-related QoL. Furthermore, minimizing corticosteroid use will benefit the clinical treatment options and outcomes of concomitant or future anti-cancer treatment. This phase III multicenter, open-label, randomized clinical trial compares the clinical efficacy of first-line bevacizumab versus standard-of-care dexamethasone for sCRN in patients with high-grade glioma (HGG) or BM.

The 2 groups in the trial

  • BevacizumabTreatment being tested

    Intravenous bevacizumab at a 600 mg flat dose every three weeks for four courses over 12 weeks

    Treatment: Bevacizumab and Dexamethasone

  • DexamethasoneExisting treatment, for comparison

    Daily oral dexamethasone followed by a protocol-based tapering dose over 12 weeks

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bevacizumab for the Treatment of Cerebral RAdiation Induced NecrosiS (BRAINS) Study: a Multicenter, Open-label, Randomized Clinical Trial to Assess the Clinical Efficacy and Cost-effectiveness of Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Plain-language title
Bevacizumab or dexamethasone as first treatment for brain damage after radiationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06888817, who can take part
Record updated
13 July 2026